<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Percutaneous transhepatic cholangiography in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Percutaneous transhepatic cholangiography in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Percutaneous transhepatic cholangiography in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ammar Sarwar, MD, FSIR</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Kruskal, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Biliary obstruction may involve the extra- or intrahepatic bile ducts and may be related to nonmalignant (eg, bile duct stones) or malignant (pancreaticobiliary cancer) causes  (<a class="graphic graphic_figure graphicRef52489" href="/d/graphic/52489.html" rel="external">figure 1</a>). Patients usually present with jaundice, abdominal pain, pruritus, and/or cholangitis. There are several options for treating biliary obstruction including endoscopic intervention, percutaneous transhepatic intervention, and surgery. Percutaneous transhepatic cholangiography (PTC) is an interventional radiologic procedure that is usually performed when endoscopic biliary access via endoscopic retrograde cholangiography (ERC) is technically limited. PTC involves transhepatic insertion of a needle into a bile duct, followed by injection of contrast material to opacify the bile ducts. PTC localizes the site of obstruction and facilitates therapeutic interventions, such as biliary drainage, removal of bile duct stones, dilation of biliary strictures, and stent placement. </p><p>This topic will discuss patient preparation, technique, postprocedure care, and adverse events related to PTC. The clinical applications for PTC are discussed in more detail separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2497.html" rel="external">"Treatment options for locally advanced, unresectable, but nonmetastatic cholangiocarcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/658.html" rel="external">"Acute cholangitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3682.html" rel="external">"Repair of common bile duct injuries"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2499.html" rel="external">"Treatment of advanced, unresectable gallbladder cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/661.html" rel="external">"Primary sclerosing cholangitis in adults: Management"</a>.)</p><p></p><p class="headingAnchor" id="H3322134583"><span class="h1">PATIENT SELECTION</span></p><p class="headingAnchor" id="H135932678"><span class="h2">Clinical applications</span><span class="headingEndMark"> — </span>The role of PTC in managing biliary disorders is primarily a therapeutic one because other methods of diagnostic testing (eg, magnetic resonance imaging with magnetic resonance cholangiopancreatography, endoscopic ultrasound) provide high diagnostic accuracy without the risks associated with percutaneous intervention. However, the initial cholangiogram helps to define biliary anatomy and guide therapeutic interventions.</p><p>PTC is indicated for patients with suspected or established biliary obstruction when endoscopic access is technically challenging or visualization of the biliary tree is limited [<a href="#rid1">1</a>]. Conditions associated with difficult biliary access (ie, unsuccessful guidewire cannulation of the common bile duct during endoscopic retrograde cholangiography [ERC]) include (see  <a class="medical medical_review" href="/d/html/675.html" rel="external">"Management of difficult biliary access during ERCP in adults"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Surgically altered anatomy (eg, Roux-en-Y gastric bypass) (see  <a class="medical medical_review" href="/d/html/15864.html" rel="external">"ERCP in patients with Roux-en-Y anatomy"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroduodenal obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Duodenal diverticulum or other anatomic variation</p><p></p><p>As an example, the intrahepatic bile ducts in patients with primary sclerosing cholangitis may not easily be opacified during ERC. For these patients, we perform PTC to define extent of disease, obtain tissue samples, dilate stricture(s), and/or perform stent placement to relieve biliary obstruction. (See  <a class="medical medical_review" href="/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma"</a>.) </p><p>PTC facilitates multiple interventions including removal of bile duct stones, sludge, or blood clots, placement of a biliary catheter for drainage, obtaining biopsies or brushings for pathology, and placement of a biliary guidewire to allow for subsequent endoscopic access  (<a class="graphic graphic_diagnosticimage graphicRef82582 graphicRef53993 graphicRef62207" href="/d/graphic/82582.html" rel="external">image 1A-C</a>).</p><p class="headingAnchor" id="H906030196"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>There are no absolute contraindications to PTC; however, the following factors may increase the risk of procedure-related adverse events:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemostatic disorders – Patients with an untreated hemostatic disorder may be at higher risk for bleeding, and we assess and optimize the coagulation status in such patients. In general, the targets for laboratory values prior to the procedure are international normalized ratio (INR) &lt;1.8 (and ideally &lt;1.5) and platelet count ≥50,000/microL. The decision to proceed with PTC and related interventions in patients with hemostatic disorders is individualized and informed by severity of coagulopathy, severity of underlying disease, procedure-related bleeding risk, and alternatives to PTC [<a href="#rid2">2-4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascites – Patients with ascites are at increased risk for leakage of ascitic fluid around the percutaneous catheter site, procedural technical difficulty due to ascites displacing the liver, and higher radiation doses [<a href="#rid1">1,5</a>]. Thus, we typically perform paracentesis prior to PTC to reduce the volume of ascites and minimize these risks [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nondilated biliary ducts – PTC may be technically limited and associated with a higher risk of adverse events in patients with nondilated intrahepatic ducts [<a href="#rid2">2,6,7</a>]. However, PTC may be accomplished in some patients with nondilated ducts, such as patients with postoperative biliary leaks. (See  <a class="medical medical_review" href="/d/html/3681.html" rel="external">"Complications of laparoscopic cholecystectomy", section on 'Biliary injury'</a>.)</p><p></p><p class="headingAnchor" id="H191045764"><span class="h1">PREPROCEDURE EVALUATION</span><span class="headingEndMark"> — </span>The diagnosis of a biliary disorder is often suspected based on presenting symptoms (abdominal pain, jaundice), laboratory studies, and imaging. Prior to PTC, we review the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing – Complete blood count, liver enzymes (aspartate aminotransferase, alanine aminotransferase), alkaline phosphatase, total bilirubin, and INR. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging – Patients referred for PTC often have dilated bile ducts, which are visible on transabdominal ultrasound or with cross-sectional imaging (eg, magnetic resonance cholangiopancreatography, computed tomography). Thus, most patients will have had imaging prior to PTC. We review imaging studies to assess options for the needle insertion site, especially if the ductal dilation involves only one or a few liver segments. However, cross-sectional imaging is not required prior to the procedure. </p><p></p><p class="headingAnchor" id="H1725406360"><span class="h1">PATIENT PREPARATION</span></p><p class="headingAnchor" id="H1701978605"><span class="h2">Adjusting medications</span><span class="headingEndMark"> — </span>The management of anticoagulants and antiplatelet agents for patients undergoing PTC is informed by the patient's risk of thromboembolic complications in the absence of therapy and the procedure-related bleeding risk. Our approach to medication adjustments for PTC is similar to the approach for other invasive procedures  (<a class="graphic graphic_table graphicRef68515" href="/d/graphic/68515.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulants – We discontinue <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> five days before the procedure and restart warfarin on the day after the procedure  (<a class="graphic graphic_algorithm graphicRef129999" href="/d/graphic/129999.html" rel="external">algorithm 1</a>). We typically discontinue direct oral anticoagulants (DOACs; eg, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>) two days before the procedure and restart DOACs on the day after the procedure.</p><p></p><p class="bulletIndent1">Peri-procedure management of anticoagulants, including bridging for patients with high thromboembolic risk, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiplatelet agents – We discontinue <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and other antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>) five days prior to the procedure. We restart antiplatelet agents on the day after the procedure. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Medications affecting hemostasis'</a>.)</p><p></p><p>We also consult with the clinician who is managing the patient's long-term anticoagulation (eg, cardiologist, neurologist) when adjusting these medications.</p><p class="headingAnchor" id="H3"><span class="h2">Sedation/anesthesia</span><span class="headingEndMark"> — </span>Options for anesthesia for PTC include moderate procedural sedation or general anesthesia. Factors informing the specific approach include risk for airway difficulty, procedure indications and expected duration (eg, catheter exchange only, need for stent or drain placement), and the patient's hemodynamic status and comorbidities. </p><p>Both moderate sedation and general anesthesia (in addition to subcutaneous injection of a local anesthetic) are reasonable options for the initial PTC in which percutaneous access is established. Insertion of the percutaneous catheter through the skin, intercostal muscles, and the liver capsule may be painful; thus, sedatives and/or analgesic medications are indicated.</p><p>We generally perform subsequent procedures (eg, exchange of a percutaneous drainage catheter) with moderate sedation plus injection of local anesthetic. Issues related to use of anesthesia outside the operating room, including the administration of local anesthetics, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/102831.html" rel="external">"Considerations for non-operating room anesthesia (NORA)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94529.html" rel="external">"Monitored anesthesia care in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics"</a>.)</p><p></p><p class="headingAnchor" id="H898551160"><span class="h2">Dietary restrictions</span><span class="headingEndMark"> — </span>Patients take nothing by mouth for three to six hours prior to the procedure [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/15698.html" rel="external">"Preoperative fasting in adults"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Antimicrobial prophylaxis</span><span class="headingEndMark"> — </span>We administer antimicrobial prophylaxis to all patients undergoing PTC, and this is consistent with society guidelines [<a href="#rid8">8</a>]. To prevent intra-abdominal infection, we use an antibiotic regimen with broad coverage against <em>Enterococcus</em> species and gram-negative organisms.   </p><p>Our first choice for antimicrobial prophylaxis is to administer <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> 1 g, intravenously, once within 60 minutes prior to the procedure. However, there is no consensus among clinicians with regard to first-line antibiotic regimen. Alternatives to ceftriaxone are [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a>/sulbactam 1.5 to 3 g, once intravenously </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9222" href="/d/drug information/9222.html" rel="external">Cefotetan</a> 1 g plus mezlocillin 4 g, once intravenously</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> 2 g plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> 1.5 mg/kg, once intravenously (see  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>)</p><p></p><p class="headingAnchor" id="H318159500"><span class="h1">PROCEDURE TECHNIQUE</span></p><p class="headingAnchor" id="H5"><span class="h2">Selecting an access site</span><span class="headingEndMark"> — </span>Selecting a percutaneous access site is guided by the location of the biliary obstruction or injury. We typically establish percutaneous access to the biliary tree through the right and/or left hepatic ducts or, less frequently, by puncturing the gallbladder.  </p><p>The right-sided approach is performed through the intercostal route, whereas left-sided access is obtained through the xiphoid (subcostal) route. Although the left-sided route has been associated with less pain, it is also associated with a higher risk of arterial injury [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Cannulating the biliary tree</span><span class="headingEndMark"> — </span>After the site is selected, the abdominal wall is cleansed with antibacterial solution. We inject <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> at the site, first superficially and then deeply into the abdominal wall. Using ultrasound or fluoroscopic guidance, we puncture a peripheral bile duct with a 21-gauge needle and then confirm the needle position by injecting a small amount of contrast material. Prior to contrast injection, we decompress the bile ducts by allowing contrast or bile to flow through the side arm of the sheath because excessive contrast injection into a dilated system increases the risk of biliary sepsis [<a href="#rid9">9</a>]. (See <a class="local">'Infection'</a> below.)</p><p>Next, we insert a guidewire through the needle into a central bile duct and then introduce a plastic drainage cannula over the guidewire. For cannula insertion, we may use sheaths and dilators to distend the tract if such maneuvers are indicated, based on the size and anatomy of the peripheral bile ducts.</p><p class="headingAnchor" id="H3384508131"><span class="h2">Establishing biliary drainage</span><span class="headingEndMark"> — </span>For patients with biliary obstruction, we may insert a catheter over the guidewire and advance it across the obstructed biliary segment and into the duodenum. This technique allows for external drainage via the percutaneous catheter and for internal drainage into the duodenum. When internal drainage has been well established, we cap the external catheter to promote internal drainage, thereby maintaining enterohepatic bile salt circulation. Internal drainage may be achieved through the internal drainage catheter or by a patent bilioenteric tract.</p><p>We typically measure serum bilirubin within 12 to 24 hours after the procedure to confirm that drainage is adequate by demonstrating a decline in bilirubin level. In our experience, patients with cholangitis will have slower drainage than those without biliary tract infection because of the higher viscosity of infected bile. (See <a class="local">'Post-procedure care'</a> below.)</p><p class="headingAnchor" id="H1906102062"><span class="h1">POST-PROCEDURE CARE</span><span class="headingEndMark"> — </span>After the procedure, patients are recovered from sedation or anesthesia. Post-anesthetic care is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14946.html" rel="external">"Overview of post-anesthetic care for adult patients"</a>.)</p><p>Post-procedure care also includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring – Most patients who undergo an initial PTC remain hospitalized overnight for observation. We typically check total bilirubin and alkaline phosphatase levels on the day following PTC. A gradual improvement in laboratory values is expected for patients who underwent biliary stenting and/or drainage [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1">Length of hospital stay is informed by complexity of procedure (eg, initial or subsequent PTC), the underlying condition, patient's clinical status and comorbidities, and risk of adverse events. As an example, we discharge patients who are hemodynamically stable and without signs of adverse events on the day after the procedure. (See <a class="local">'Adverse events'</a> below.)</p><p></p><p class="bulletIndent1">We instruct patients to monitor the drain site for catheter dislodgement, peri-catheter leakage, and catheter occlusion. Patients with an occluded catheter often present with acute cholangitis (eg, fever, abdominal pain, jaundice). (See  <a class="medical medical_review" href="/d/html/658.html" rel="external">"Acute cholangitis: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Patients who had a follow-up PTC for catheter exchange or removal are usually discharged on the same day after recovering from anesthesia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diet – Patients may resume their normal diet after the procedure. </p><p></p><p class="headingAnchor" id="H8"><span class="h1">ADVERSE EVENTS</span></p><p class="headingAnchor" id="H3577144965"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>PTC is generally regarded as a safe procedure, but adverse events can occur even when standard infection control measures and good technique are used. Estimated rates of major complications range from 4 to 9 percent, and estimated rates of minor complications range from 2 to 38 percent [<a href="#rid2">2</a>]. Major complications related to PTC with biliary drainage include cholangitis and bleeding, whereas minor complications include catheter occlusion (8 percent), catheter dislodgement (6 percent), and leakage around the catheter (3 percent) [<a href="#rid3">3,10</a>]. (See <a class="local">'Infection'</a> below and <a class="local">'Bleeding'</a> below.) </p><p class="headingAnchor" id="H3617933644"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Cholangitis is a major infectious complication of PTC, with reported rates ranging from 5 to 9 percent of procedures, while the rates of post-procedure sepsis are lower and range from 1 to 2 percent [<a href="#rid2">2,3</a>]. The management of cholangitis includes decompression of the obstructed bile ducts and antimicrobial therapy, and these issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/658.html" rel="external">"Acute cholangitis: Clinical manifestations, diagnosis, and management", section on 'Management'</a>.)</p><p>Other reported infectious or inflammatory complications include abscess, peritonitis, cholecystitis, and pancreatitis [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H1831175774"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>Hemobilia (ie, bleeding into the biliary system) is a potential complication of PTC with biliary intervention that results from communication between the biliary tract and a vascular structure. Reported rates of hemobilia range from 2 to 20 percent [<a href="#rid3">3</a>]. Severe hemobilia is defined as continuous bloody output into the drainage bag, drop in hemoglobin level, and/or hemodynamic instability; however, severe bleeding is uncommon following PTC. Causes of severe hemobilia include communication of the biliary tract with a major blood vessel such as the portal vein or a branch of the hepatic artery [<a href="#rid11">11-13</a>].  </p><p>Most episodes of bleeding after PTC are typically self-limiting or are treated with transcatheter endovascular embolization. In a study including 3110 patients who underwent 3780 percutaneous transhepatic biliary drainage procedures, hepatic arterial injury occurred after 72 procedures (2 percent) [<a href="#rid11">11</a>]. All patients were treated with transcatheter embolization, with technical and clinical success rates of 100 and 96 percent, respectively. While hepatic artery injury is a rare complication of percutaneous transhepatic biliary drainage, intrahepatic ductal dilation and left-sided puncture have been identified risk factors [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/2540.html" rel="external">"Angiographic control of nonvariceal gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>–<strong> </strong>Percutaneous transhepatic cholangiography (PTC) is an interventional radiologic procedure that involves transhepatic insertion of a needle into a bile duct, followed by injection of contrast material to opacify the bile ducts. PTC and subsequent interventions are often performed when endoscopic retrograde cholangiography (ERC)-guided biliary access is challenging or limited in patients with biliary obstruction. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Conditions associated with difficult endoscopic biliary access include surgically altered anatomy (eg, Roux-en-Y gastric bypass), gastroduodenal obstruction, and duodenal diverticulum. (See  <a class="medical medical_review" href="/d/html/675.html" rel="external">"Management of difficult biliary access during ERCP in adults"</a>.)</p><p></p><p class="bulletIndent1">PTC facilitates multiple interventions including removal of bile duct stones, dilation of biliary strictures, placement of a biliary stent, and sampling tissue with biopsies or brushings. (See <a class="local">'Clinical applications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedure evaluation</strong> – The diagnosis of a biliary disorder is often suspected based on presenting symptoms (abdominal pain, jaundice), laboratory studies, and imaging. Prior to PTC, we review the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory testing – Complete blood count, liver enzymes (aspartate aminotransferase, alanine aminotransferase), alkaline phosphatase, total bilirubin, and international normalized ratio (INR). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Imaging – Prior to referral for PTC, most patients will have had imaging (eg, transabdominal ultrasound, magnetic resonance cholangiopancreatography, computed tomography). We review prior imaging to assess biliary tree anatomy and options for the needle insertion site. However, cross-sectional imaging is not required prior to the procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient preparation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjusting medications – Our general approach to preprocedure medication adjustments includes  (<a class="graphic graphic_table graphicRef68515" href="/d/graphic/68515.html" rel="external">table 1</a>) (see <a class="local">'Adjusting medications'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anticoagulants – We discontinue <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> five days before the procedure and restart warfarin on the day after the procedure. We typically discontinue direct oral anticoagulants (DOACs) two days before the procedure and restart DOACs on the day after the procedure  (<a class="graphic graphic_algorithm graphicRef129999" href="/d/graphic/129999.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antiplatelet agents – We discontinue <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and other antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>) five days prior to the procedure. We restart antiplatelet agents on the day after the procedure. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management"</a>.)</p><p></p><p class="bulletIndent2">We also consult with the clinician who is managing the patient's long-term anticoagulation (eg, cardiologist, neurologist) when adjusting these medications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antimicrobial prophylaxis – We use antibiotic prophylaxis for all patients undergoing PTC. We suggest <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> as first-line prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) because of its spectrum of activity and clinical experience. We typically administer ceftriaxone 1 g, intravenously, once within 60 minutes prior to the procedure. (See <a class="local">'Antimicrobial prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-procedure care</strong> – After PTC, patients are recovered from sedation or anesthesia. (See  <a class="medical medical_review" href="/d/html/14946.html" rel="external">"Overview of post-anesthetic care for adult patients"</a>.)</p><p></p><p class="bulletIndent1">Most patients who undergo an initial PTC remain hospitalized overnight for observation. We typically check serum total bilirubin and alkaline phosphatase on the following day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events </strong>– PTC is generally regarded as a safe procedure, but adverse events can occur even when standard infection control measures and good technique are used. Major complications related to PTC with biliary drainage include cholangitis and bleeding, whereas minor complications include drain occlusion, drain dislodgement, and leakage around the drain. (See <a class="local">'Adverse events'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Perez-Johnston R, Deipolyi AR, Covey AM. Percutaneous Biliary Interventions. Gastroenterol Clin North Am 2018; 47:621.</a></li><li><a class="nounderline abstract_t">Devane AM, Annam A, Brody L, et al. Society of Interventional Radiology Quality Improvement Standards for Percutaneous Cholecystostomy and Percutaneous Transhepatic Biliary Interventions. J Vasc Interv Radiol 2020; 31:1849.</a></li><li><a class="nounderline abstract_t">Das M, van der Leij C, Katoh M, et al. CIRSE Standards of Practice on Percutaneous Transhepatic Cholangiography, Biliary Drainage and Stenting. Cardiovasc Intervent Radiol 2021; 44:1499.</a></li><li><a class="nounderline abstract_t">Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30:1168.</a></li><li><a class="nounderline abstract_t">Duncan C, Hunt SJ, Gade T, et al. Outcomes of Percutaneous Cholecystostomy in the Presence of Ascites. J Vasc Interv Radiol 2016; 27:562.</a></li><li><a class="nounderline abstract_t">Cozzi G, Severini A, Civelli E, et al. Percutaneous transhepatic biliary drainage in the management of postsurgical biliary leaks in patients with nondilated intrahepatic bile ducts. Cardiovasc Intervent Radiol 2006; 29:380.</a></li><li><a class="nounderline abstract_t">Kühn JP, Busemann A, Lerch MM, et al. Percutaneous biliary drainage in patients with nondilated intrahepatic bile ducts compared with patients with dilated intrahepatic bile ducts. AJR Am J Roentgenol 2010; 195:851.</a></li><li><a class="nounderline abstract_t">Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol 2018; 29:1483.</a></li><li><a class="nounderline abstract_t">Wu SM, Marchant LK, Haskal ZJ. Percutaneous interventions in the biliary tree. Semin Roentgenol 1997; 32:228.</a></li><li><a class="nounderline abstract_t">Nennstiel S, Weber A, Frick G, et al. Drainage-related Complications in Percutaneous Transhepatic Biliary Drainage: An Analysis Over 10 Years. J Clin Gastroenterol 2015; 49:764.</a></li><li><a class="nounderline abstract_t">Choi SH, Gwon DI, Ko GY, et al. Hepatic arterial injuries in 3110 patients following percutaneous transhepatic biliary drainage. Radiology 2011; 261:969.</a></li><li><a class="nounderline abstract_t">Shiau EL, Liang HL, Lin YH, et al. The Complication of Hepatic Artery Injuries of 1,304 Percutaneous Transhepatic Biliary Drainage in a Single Institute. J Vasc Interv Radiol 2017; 28:1025.</a></li><li><a class="nounderline abstract_t">Molina H, Chan MM, Lewandowski RJ, et al. Complications of Percutaneous Biliary Procedures. Semin Intervent Radiol 2021; 38:364.</a></li></ol></div><div id="topicVersionRevision">Topic 671 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30115441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Percutaneous Biliary Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33011014" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Society of Interventional Radiology Quality Improvement Standards for Percutaneous Cholecystostomy and Percutaneous Transhepatic Biliary Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34327586" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CIRSE Standards of Practice on Percutaneous Transhepatic Cholangiography, Biliary Drainage and Stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229333" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26898624" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes of Percutaneous Cholecystostomy in the Presence of Ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502179" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Percutaneous transhepatic biliary drainage in the management of postsurgical biliary leaks in patients with nondilated intrahepatic bile ducts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858809" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Percutaneous biliary drainage in patients with nondilated intrahepatic bile ducts compared with patients with dilated intrahepatic bile ducts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30274857" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253072" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Percutaneous interventions in the biliary tree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25518004" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Drainage-related Complications in Percutaneous Transhepatic Biliary Drainage: An Analysis Over 10 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21875851" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatic arterial injuries in 3110 patients following percutaneous transhepatic biliary drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461005" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Complication of Hepatic Artery Injuries of 1,304 Percutaneous Transhepatic Biliary Drainage in a Single Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34393347" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complications of Percutaneous Biliary Procedures.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
